Rebecca L. Olin, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Rebecca L. Olin, MD

Assistant Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-2421 (appts)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Hematopoietic Malignancies

Education

Amherst College, Amherst, MA, B.A., 1999, Biology
University of Pennsylvania School of Medicine, M.D., 2003
University of Pennsylvania, M.S., 2009, Clinical Epidemiology


Professional Experience

  • 2003-2006
    Internship and residency, Internal Medicine, University of Pennsylvania Hospital
  • 2006-2009
    Fellowship, Hematology/Oncology, University of Pennsylvania Hospital
  • 2007-2008
    Chief Fellow, Hematology/Oncology, University of Pennsylvania Hospital
  • 2009-present
    Assistant Clinical Professor of Medicine, University of California San Francisco

Honors & Awards

  • 1999
    Phi Beta Kappa, Amherst College
  • 2002
    Alpha Omega Alpha, early induction, University of Pennsylvania
  • 2002
    Botelho Prize for Excellence in Basic Science
  • 2003
    Dr. Spencer Morris Prize
  • 2005
    American Society of Hematology Trainee Award
  • 2008
    American Society of Hematology Travel Award

Selected Publications

  1. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016 Jan 1; 122(1):116-23.
    View on PubMed
  2. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  3. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.
    View on PubMed
  4. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  5. David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. J Clin Oncol. 2013 Oct 1; 31(28):3608-9.
    View on PubMed
  6. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol. 2010 Apr; 85(4):255-60.
    View on PubMed
  7. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009 Mar; 43(5):417-22.
    View on PubMed
  8. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008 Sep; 83(9):747-9.
    View on PubMed
  9. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007 Mar-Apr; 13(2):211-2.
    View on PubMed

Go to UCSF Profiles, powered by CTSI